OncoMatch/Clinical Trials/NCT06212583
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
Is NCT06212583 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including niraparib/abiraterone acetate and Androgen deprivation therapy (ADT) for prostate cancer.
Treatment: niraparib/abiraterone acetate · Androgen deprivation therapy (ADT) — The purpose of this research study is to compare the effects, good and/or bad, of using the standard of care treatment, hormonal therapy + Stereotactic Ablative Radiation (SABR) to the metastatic lesions, compared to standard of care and addition of 6-months of niraparib/abiraterone acetate combination pills and prednisone for participants with recurrent metastatic prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Required: ATM pathogenic mutation
Required: BRCA1 pathogenic mutation
Required: BRCA2 pathogenic mutation
Required: BRIP1 pathogenic mutation
Required: CHEK2 pathogenic mutation
Required: FANCA pathogenic mutation
Required: MUTYH pathogenic mutation
Required: PALB2 pathogenic mutation
Required: RAD51B pathogenic mutation
Required: RAD54L pathogenic mutation
Required: TP53 pathogenic mutation
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: parp inhibitor
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5 x 10^9/L; Hemoglobin ≥9.0 g/dL, independent of transfusions for at least 28 days; Platelet count ≥100 x 10^9/L
Kidney function
Creatinine <2 x upper limit of normal (ULN); Serum potassium ≥3.5 mmol/L
Liver function
Serum total bilirubin ≤1.5× ULN or direct bilirubin ≤1 x ULN (Gilbert's syndrome exception); AST or ALT ≤3 × ULN; Moderate or severe hepatic impairment (Class B and C per Child-Pugh classification system) [excluded]
Adequate hematologic, renal, and hepatic function at screening defined as follows: Absolute neutrophil count ≥1.5 x 10^9/L; Hemoglobin ≥9.0 g/dL, independent of transfusions for at least 28 days; Platelet count ≥100 x 10^9/L; Creatinine <2 x upper limit of normal (ULN); Serum potassium ≥3.5 mmol/L; Serum total bilirubin ≤1.5× ULN or direct bilirubin ≤1 x ULN (Gilbert's syndrome exception); AST or ALT ≤3 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Maryland Greenebaum Cancer Center · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify